impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13

 

  1. Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Italy.
  2. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  3. Institute of Paediatrics, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome; and Università Cattolica Sacro Cuore, Rome, Italy.
  4. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  5. Department of Experimental and Clinical Medicine, University of Florence, Italy.
  6. Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari, Italy.
  7. Interdisciplinary Department of Medicine, Rheumatology Unit, University of Bari, Italy.
  8. Rheumatology Unit, Department of Emergency and Organ Transplantation (DETO), University of Bari, Italy.
  9. Department of Ophthalmology and Otolaryngology, University of Bari, Italy.
  10. Department of Ophthalmology and Otolaryngology, University of Bari, Italy.
  11. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
  12. Research Center of Systemic Autoinflammatory Diseases and Behçet’s Disease and Rheumatology-Ophthalmology Collaborative Uveitis Center, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy. cantariniluca@hotmail.com
  13. Ophthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Italy.

CER12352
2020 Vol.38, N°4
PI 0621, PF 0625
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 31694738 [PubMed]

Received: 19/04/2019
Accepted : 22/07/2019
In Press: 17/10/2019
Published: 28/07/2020

Abstract

OBJECTIVES:
To assess the efficacy of anti-tumour necrosis factor (TNF)-α agents in the treatment of refractory uveitic macular oedema (UME).
METHODS:
Patients with refractory UME treated with TNF-α blockers were retrospectively enrolled. Central macular thickness (CMT) was assessed at optical coherence tomography (OCT) at the start of TNF-α inhibition, after 3 and 12 months, and at the last follow-up visit.
RESULTS:
Thirty-six patients (56 eyes with UME) were enrolled. The mean follow-up period was 29.9±40.8 (4-184) months. A statistically significant decrease was observed in the frequency of UME (p<0.0001) and in the mean CMT values (p<0.0001) during the study period. Best corrected visual acuity improved in 35 eyes (62.5%), remained stable in 12 eyes (21.4%), reduced in 9 eyes (16.1%). The mean corticosteroid dosage significantly decreased during the study period (p=0.016).
CONCLUSIONS:
TNF-α inhibitors represent a useful treatment in patients with severe or resistant UME.

Rheumatology Article